Monopar Therapeutics Inc.
General ticker "MNPR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $678.2M (TTM average)
Monopar Therapeutics Inc. follows the US Stock Market performance with the rate: 48.1%.
Estimated limits based on current volatility of 4.7%: low 75.01$, high 82.36$
Factors to consider:
- Total employees count: 10 (-16.7%) as of 2023
- Top business risk factors: Limited operating history, Economic downturns and volatility, Intellectual property risks, Inexperience in new services, Cybersecurity threats
- Current price 232.7% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [8.17$, 23.88$]
- 2025-12-31 to 2026-12-31 estimated range: [4.67$, 14.02$]
Financial Metrics affecting the MNPR estimates:
- Negative: with PPE of -6.8 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -6.87 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Negative: -0.75 < Inventory ratio change, % of 0
- Negative: -0.15 < Industry inventory ratio change (median), % of 0
- Negative: negative Industry operating income (median)
Short-term MNPR quotes
Long-term MNPR plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $10.54MM | $8.83MM | $16.16MM |
| Operating Income | $-10.54MM | $-8.83MM | $-16.16MM |
| Non-Operating Income | $0.04MM | $0.43MM | $0.58MM |
| R&D Expense | $7.59MM | $5.60MM | $13.01MM |
| Income(Loss) | $-10.50MM | $-8.40MM | $-15.59MM |
| Profit(Loss)* | $-10.52MM | $-8.40MM | $-15.59MM |
| Stockholders Equity | $10.09MM | $5.59MM | $55.04MM |
| Assets | $13.23MM | $7.35MM | $60.29MM |
| Operating Cash Flow | $-7.23MM | $-7.86MM | $-6.40MM |
| Investing Cash Flow | $-4.92MM | $4.93MM | $-14.34MM |
| Financing Cash Flow | $0.03MM | $2.03MM | $59.29MM |
| Earnings Per Share** | $-0.83 | $-0.58 | $-4.11 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.